De quoi consiste cette étude ?

Participants will take part in a one-on-one interview (in person or online) to share thoughts on reminders and changes in behavior that should be tracked by the system. Interviews will last about 60 minutes. A short follow-up (20 minutes or less) may also be requested later to provide extra feedback on the system’s design.

De quoi consiste cette étude ?

Behavioral and emotional changes often accompany dementia and are a leading cause of long-term care placement, even more so than cognitive decline. This study is the first to explore how family caregivers make treatment decisions in response to these emotional and behavioural symptoms. We are interested in understanding whether caregivers turn to medications, consider non-pharmacological strategies such as environmental modifications, or use a combination of both. Using a quantitative behavioural economics model, this study will examine how caregivers weigh the risks and benefits of different treatment options. We are particularly interested in decision-making related to dopaminergic medications (formerly known as “antipsychotics”), which are commonly prescribed despite known risks for people with dementia. The information gathered will help guide the development of resources to better support family caregivers in navigating treatment decisions. Participation involves completing an anonymous online survey and is open to family caregivers involved in medical decision-making for a relative or close friend with dementia.

De quoi consiste cette étude ?

In collaboration with our South Asian community collaborators, our goal is to gain an in-depth understanding of new immigrant, multigenerational, South Asian family caregiving for a relative with dementia amidst COVID-19. The goal is to inform future family-centered, healthcare interventions aimed at supporting equity deserving families during times of crisis.

To achieve our goal, we are starting to recruit family care partners living in a multigenerational home and caring for a relative with dementia from each of the four groups of South Asian families. We will be using a multiple case study to examine new immigrant, multigenerational caregiving for a relative with dementia from the perspective of four groups of South Asian families; 1) Pakistani, 2) Bangladeshi, 3) Indian, and 4) Sri Lankan. We will also be using secondary data sources, including genograms, ecoMaps, and key documents.

We will be conducting interviews with a family care partners from each of the four groups. Following these interviews, we will hold four focus groups with a new purposeful sample of South Asian multigenerational care partners to understand if the findings from the interviews reflect their caregiving experiences thereby increasing the reliability of the study findings.

De quoi consiste cette étude ?

In this study we aim to explore the motivations and impacts of disclosure a personal diagnosis of dementia or being a care partner on social media. The overall goal of the study is to develop an evidence-based resource to promote benefits of social media for the dementia community while minimizing its harms.

De quoi consiste cette étude ?

CAN-PROTECT is a Canada-wide online study recruiting participants and caregivers of persons with dementia to explore how lifestyle, background, and caretaking factors affect our health, quality of life, cognition, behaviour, and function as we age. CAN-PROTECT data will be analyzed and jointly published by the University of Calgary in partnership with the University of Exeter.

De quoi consiste cette étude ?

Notre étude vise à développer des biomarqueurs diagnostiques non invasifs pour la maladie d'Alzheimer. Nous nous concentrons sur l'évaluation du potentiel de la QSM et de la FEO pour différencier la maladie d’Alzheimer, le trouble cognitif léger (MCI) et les populations sans trouble cognitif et pour prédire la pathologie amyloïde et tau, en utilisant une approche de biologie des systèmes. S'appuyant sur la cohorte TRIAD de l'Université McGill, l'étude utilise l'imagerie avancée et l'apprentissage automatique pour prédire la présence d'amyloïde et de tau, ce qui pourrait transformer le diagnostic et le traitement de la maladie d'Alzheimer. D'un point de vue méthodologique, il s'agit de prétraiter les données de neuro-imagerie et d'utiliser des classificateurs d'apprentissage automatique pour analyser ces caractéristiques. Les résultats attendus comprennent la validation de la QSM et de la FEO en tant que biomarqueurs non invasifs de la maladie d'Alzheimer, l'établissement de leur corrélation avec les protéines amyloïdes et tau, et le développement de modèles prédictifs pour la prise de décision clinique, ce qui pourrait entraîner des avancées significatives dans le diagnostic de la maladie d'Alzheimer.

De quoi consiste cette étude ?

Les aidants ont une expérience directe de la progression du trouble neurocognitif de la personne aidée. Ils jouent un rôle essentiel dans l’évaluation des avantages réels du traitement et dans la prise de décision sur l’à-propos de garder la personne à la maison ou d’envisager d’autres niveaux de soins. Le but de cette étude est de mettre au point un nouveau critère permettant d’évaluer le trouble neurocognitif signalé et pondéré par l'aidant.